Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Fáze III klinické studie meningokokové polysacharidové vakcíny skupiny A a C

Randomizovaná, dvojitě zaslepená, kontrolovaná, non-inferiorní studie fáze III meningokokové polysacharidové vakcíny skupiny A a C u zdravých dětí ve věku 2-6 let

This study is a randomized, double-blinded, and controlled phase III clinical trial of the Group A and C meningococcal polysaccharide vaccine to evaluate the safety and immunogenicity of the vaccine in healthy infants aged 2-6 years.

Přehled studie

Detailní popis

This study was divided into two stages. The first stage study was an early safety assessment study among 80 subjects. The first stage study was conducted gradually in 20 subjects aged 18-50 years, 20 subjects aged 7-17 years, and 40 subjects aged 2-6 years. The second phase was a randomized, double-blind, controlled, non-inferiority phase III clinical trial in 1200 healthy infants aged 2-6 years, to evaluate the immunogenicity and safety of the experimantal vaccine after immunization.

Typ studie

Intervenční

Zápis (Aktuální)

1280

Fáze

  • Fáze 3

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní místa

    • Yunnan
      • Kunming, Yunnan, Čína
        • Yunnan Center for Disease Control and Prevention

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

2 roky až 50 let (Dítě, Dospělý)

Přijímá zdravé dobrovolníky

Ano

Pohlaví způsobilá ke studiu

Všechno

Popis

  • The First stage study (An early safety assessment study):

  • 18-50 years group:

    • Inclusion Criteria:

      1. Healthy adults aged 18 to 50 years.
      2. Proven legal identity.
      3. Participants should understand the contents of the informed consent form, the vaccine in this trial, voluntarily sign the informed consent form, and be capable of using thermometers, scales, and filling in diary cards and contact cards as required.
      4. Participants should be able to communicate well with investigators, understand and comply with the requirements of this trial.
      5. Axillary temperature ≤37.0℃.
    • Exclusion Criteria:

      1. Contraindications for vaccination.
      2. History of allergy to vaccines or drugs.
      3. History of Epidemic Cerebrospinal Meningitis.
      4. Immunization with any Group A meningococcal conjugate vaccine or polysaccharide vaccine within 12 months.
      5. Immunization with any Group A and C meningococcal conjugate vaccine or polysaccharide vaccine within 3 years.
      6. Immunization with any vaccine within 30 days.
      7. Patients with convulsion, epilepsy, encephalopathy and psychiatric history or family history of epilepsy.
      8. History of abnormal clinical manifestations and serious diseases to be excluded, including but not limited to nervous system, cardiovascular system, blood and lymphatic system, immune system, kidney, liver, gastrointestinal tract, respiratory system, metabolism, bones and other system diseases, and a history of malignant tumors.
      9. Those who developed acute disease or acute attack of chronic disease.
      10. Surgical removal of spleen or other important organs for any reason.
      11. History of thrombocytopenia or other coagulation disorders may cause contraindication of subcutaneous injection.
      12. Blood products such as immunoglobulin were received within 30 days before vaccination.
      13. Have received immunosuppressive therapy or other immunomodulatory drugs within 6 months before signing the informed consent form (Note: inhaled or topical hormone drugs, except those with an interval of 14 days or more from the date of signing the informed consent form).
      14. Those who participated in other clinical studies.
      15. Participants who have a positive pregnancy test, or are breastfeeding, or plan to become pregnant, or plan to donate sperm or eggs from the screening to 12 months after the second vaccination.
      16. Any other situations judged by investigators as not suitable for participating in this study.
  • 7-17 years group:

    • Inclusion Criteria

      1. Healthy volunteer aged 7 to 17 years.
      2. Proven legal identity.
      3. Participants and their legal guardians should understand the contents of the informed consent form, the vaccine in this trial, voluntarily sign the informed consent form, and be capable of using thermometers, scales, and filling in diary cards and contact cards as required.
      4. Participants and their legal guardians should be able to communicate well with investigators, understand and comply with the requirements of this trial.
      5. Axillary temperature ≤37.0℃.
    • Exclusion Criteria:

      1. Contraindications for vaccination.
      2. History of allergy to vaccines or drugs.
      3. History of Epidemic Cerebrospinal Meningitis.
      4. Immunization with any Group A meningococcal conjugate vaccine or polysaccharide vaccine within 12 months.
      5. Immunization with any Group A meningococcal conjugate vaccine or polysaccharide vaccine within 3 years.
      6. Immunization with any vaccine within 30 days.
      7. Patients with convulsion, epilepsy, encephalopathy and psychiatric history or family history of epilepsy.
      8. Participant who has congenital heart disease, congenital malformation, Down's syndrome, sickle cell anemia or severe diseases with previous clinical manifestations that need to be excluded, including but not limited to nervous system, genetic defect disease (such as faba bean disease), cardiovascular system, blood and lymphatic system, immune system, kidney, liver, gastrointestinal tract, respiratory system, metabolism and bone system diseases, and History of malignant tumor.
      9. Those who developed acute disease or acute attack of chronic disease.
      10. Surgical removal of spleen or other important organs for any reason.
      11. History of thrombocytopenia or other coagulation disorders may cause contraindication of subcutaneous injection.
      12. Blood products such as immunoglobulin were received within 30 days before vaccination.
      13. Have received immunosuppressive therapy or other immunomodulatory drugs within 6 months before signing the informed consent form (Note: inhaled or topical hormone drugs, except those with an interval of 14 days or more from the date of signing the informed consent form).
      14. Those who participated in other clinical studies.
      15. Women with positive pregnancy test after menarche.
      16. Any other situations judged by investigators as not suitable for participating in this study.
  • 2-6 years group:

    • Inclusion Criteria

      1. Healthy children aged 2 to 6 years.
      2. Proven legal identity.
      3. Participants' legal guardians should understand the contents of the informed consent form, the vaccine in this trial, voluntarily sign the informed consent form, and be capable of using thermometers, scales, and filling in diary cards and contact cards as required.
      4. Participants' legal guardians should be able to communicate well with investigators, understand and comply with the requirements of this trial.
      5. Axillary temperature ≤37.0℃.
    • Exclusion Criteria:

      1. Contraindications for vaccination.
      2. History of allergy to vaccines or drugs.
      3. History of Epidemic Cerebrospinal Meningitis.
      4. Immunization with any Group A and C meningococcal conjugate vaccine or polysaccharide vaccine.
      5. Immunization with any Group A meningococcal conjugate vaccine or polysaccharide vaccine within 12 months.
      6. They were vaccinated with live attenuated vaccine within 14 days before vaccination and subunit or inactivated vaccine within 7 days (copy of vaccination certificate of subjects);
      7. Participants with convulsion, epilepsy, encephalopathy and psychiatric history or family history of epilepsy.
      8. Participant who has congenital heart disease, congenital malformation, Down's syndrome, sickle cell anemia or severe diseases with previous clinical manifestations that need to be excluded, including but not limited to nervous system, genetic defect disease (such as faba bean disease), cardiovascular system, blood and lymphatic system, immune system, kidney, liver, gastrointestinal tract, respiratory system, metabolism and bone system diseases, and History of malignant tumor.
      9. Those who developed acute disease or acute attack of chronic disease.
      10. Surgical removal of spleen or other important organs for any reason.
      11. History of thrombocytopenia or other coagulation disorders may cause contraindication of subcutaneous injection.
      12. Blood products such as immunoglobulin were received within 30 days before vaccination.
      13. Have received immunosuppressive therapy or other immunomodulatory drugs within 6 months before signing the informed consent form (Note: inhaled or topical hormone drugs, except those with an interval of 14 days or more from the date of signing the informed consent form).
      14. Those who participated in other clinical studies.
      15. Any other situations judged by investigators as not suitable for participating in this study.

The Second stage study (A phase III clinical trial )

  • Inclusion Criteria

    1. Healthy children aged 2 to 6 years.
    2. Proven legal identity.
    3. Participants' legal guardians should understand the contents of the informed consent form, the vaccine in this trial, voluntarily sign the informed consent form, and be capable of using thermometers, scales, and filling in diary cards and contact cards as required.
    4. Participants' legal guardians should be able to communicate well with investigators, understand and comply with the requirements of this trial.
    5. Axillary temperature ≤37.0℃.
  • Exclusion Criteria:

    1. Contraindications for vaccination.
    2. History of allergy to vaccines or drugs.
    3. History of Epidemic Cerebrospinal Meningitis.
    4. Immunization with any Group A and C meningococcal conjugate vaccine or polysaccharide vaccine.
    5. Immunization with any Group A meningococcal conjugate vaccine or polysaccharide vaccine within 12 months.
    6. They were vaccinated with live attenuated vaccine within 14 days before vaccination and subunit or inactivated vaccine within 7 days (copy of vaccination certificate of subjects);
    7. Participants with convulsion, epilepsy, encephalopathy and psychiatric history or family history of epilepsy.
    8. Participant who has congenital heart disease, congenital malformation, Down's syndrome, sickle cell anemia or severe diseases with previous clinical manifestations that need to be excluded, including but not limited to nervous system, genetic defect disease (such as faba bean disease), cardiovascular system, blood and lymphatic system, immune system, kidney, liver, gastrointestinal tract, respiratory system, metabolism and bone system diseases, and History of malignant tumor.
    9. Those who developed acute disease or acute attack of chronic disease.
    10. Surgical removal of spleen or other important organs for any reason.
    11. History of thrombocytopenia or other coagulation disorders may cause contraindication of subcutaneous injection.
    12. Blood products such as immunoglobulin were received within 30 days before vaccination.
    13. Have received immunosuppressive therapy or other immunomodulatory drugs within 6 months before signing the informed consent form (Note: inhaled or topical hormone drugs, except those with an interval of 14 days or more from the date of signing the informed consent form).
    14. Those who participated in other clinical studies.
    15. Any other situations judged by investigators as not suitable for participating in this study.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Prevence
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Čtyřnásobek

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: Experimental Vaccine

One dose of Experimental Group A and C meningococcal polysaccharide vaccine

One dose of Experimental Group A and C meningococcal polysaccharide vaccine

Aktivní komparátor: Active Comparator Vaccine

One dose of Control Group A and C meningococcal polysaccharide vaccine

One dose of Control Group A and C meningococcal polysaccharide vaccine

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Seroconversion rate of Group A meningococcal bactericidal antibody
Časové okno: 28 days after vaccination

Seroconversion rate of Group A meningococcal bactericidal antibody at day 28 after vaccination

28 days after vaccination
Seroconversion rate of Group C meningococcal bactericidal antibody
Časové okno: 28 days after vaccination

Seroconversion rate of Group C meningococcal bactericidal antibody at day 28 after vaccination

28 days after vaccination

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Adverse reactions/events rate
Časové okno: 7 days after vaccination

Occurence of adverse reactions/events after vaccination

7 days after vaccination
Adverse reactions/events rate
Časové okno: 28 days after vaccination

Occurence of adverse reactions/events after vaccination

28 days after vaccination
Serious adverse events
Časové okno: 6 months after the second vaccination

Occurence of Serious adverse events after vaccination

6 months after the second vaccination
GMT of Group A meningococcal bactericidal antibody
Časové okno: 28 days after the second vaccination

GMT of Group A meningococcal bactericidal antibody at day 28 after the second vaccination

28 days after the second vaccination
GMT of Group C meningococcal bactericidal antibody
Časové okno: 28 days after the second vaccination

GMT of Group C meningococcal bactericidal antibody at day 28 after the second vaccination

28 days after the second vaccination

Další výstupní opatření

Měření výsledku
Popis opatření
Časové okno
GMT of IgG antibody against Hepatitis A
Časové okno: 28 days after the second vaccination

GMT of IgG antibody against Hepatitis A at day 28 after vaccination

28 days after the second vaccination
Seropositive rate of IgG antibody against Hepatitis A
Časové okno: 28 days after the second vaccination

Seropositive rate of IgG antibody against Hepatitis A at day 28 after vaccination

28 days after the second vaccination

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Vyšetřovatelé

  • Vrchní vyšetřovatel: Yan Zheng, Mater, Yunnan Center for Disease Control and Prevention

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

15. září 2020

Primární dokončení (Aktuální)

29. dubna 2021

Dokončení studie (Aktuální)

26. září 2021

Termíny zápisu do studia

První předloženo

8. prosince 2020

První předloženo, které splnilo kritéria kontroly kvality

28. prosince 2020

První zveřejněno (Aktuální)

30. prosince 2020

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

29. září 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

24. září 2026

Naposledy ověřeno

1. září 2026

Více informací

Termíny související s touto studií

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

NE

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit